These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...

2025年1月29日， Akero Therapeutics（AKRO）披露11笔公司内部人交易情况。董事Cheng Andrew于2025年1月27日卖出2.42万股。

Akero Therapeutics (AKRO) reported 96-week data in its trial of advanced MASH patients, and there seem really significant ...

Akero Therapeutics nearly doubled Monday — and pulled 89bio shares higher — after the company's treatment for MASH ...

(ETNB) stock jumped 40% Monday, stoked by positive data for Akero's (AKRO) drug efruxifermin in the treatment of compensated ...

After missing the primary endpoint in the Phase IIb SYMMETRY trial, Akero Therapeutics’ lead molecule, efruxifermin, showed ...

Patients with metabolic dysfunction-associated steotohepatitis (MASH) who are already taking a glucagon-like peptide-1 ...

Akero Therapeutics has hit a home run, reporting statistically significant results in two key 96-week metabolic ...

Leerink Partners analyst Thomas Smith has maintained their bullish stance on ETNB stock, giving a Buy rating on January 2.Stay Ahead of the ...

Non-alcoholic steatohepatitis (NASH) is a condition characterized by accumulation of fat, inflammation and injury in liver cells in people who consume little or no alcohol. It is the progressive ...

目前全球有超 400 款创新药针对 NASH 开展临床试验，3 款已在部分国家获批上市，16 款处于临床 3 期。药物研发重点关注脂质积聚、胰岛素抵抗、纤维化和炎症等方面，主要靶点包括 GLP - 1R、THR - β、FGF21、PPAR 等。GLP - 1R 靶点有多款激动剂在研，部分产品临床 2/3 ...

• 在研新药：以GLP-1R、THR-β、FGF21、PPAR等靶点为主，多款产品临床疗效显著。目前全球有超400款创新药正在开展NASH适应症的临 床试验，3款药物赛格 ...